FDA Approves Expanded Liquid Biopsy Panel
Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.
By
Kathryn Wighton
May 20, 2026
Clinical Scorecard: FDA Approves Expanded Liquid Biopsy Panel
At a Glance
Category Detail
Condition Advanced Cancer Key Mechanisms Comprehensive molecular profiling through genomic and epigenomic analysis from a blood sample. Target Population Patients with advanced cancer, including those with non–small cell lung cancer, colorectal cancer, and advanced breast cancer with ESR1 mutations. Care Setting Applicable across multiple stages of cancer care, including treatment selection, recurrence monitoring, and cancer screening.
Key Highlights
Largest FDA-approved liquid biopsy panel with a genomic footprint 100 times broader than previous versions. Combines genomic and epigenomic profiling to enhance circulating tumor DNA detection sensitivity. Identifies clinically actionable findings not detectable through genomic analysis alone. Results available within 7 days and usable regardless of tissue availability. Covered by Medicare and commercial insurers for over 300 million lives. Guideline-Based Recommendations
Diagnosis
Utilize the Guardant360 Liquid CDx for comprehensive tumor profiling. Management
Support treatment selection for advanced cancer therapies, particularly in non–small cell lung cancer and colorectal cancer. Monitoring & Follow-up
Employ for recurrence monitoring and cancer screening. Risks
Consider the limitations of liquid biopsy in specific clinical scenarios. Patient & Prescribing Data
Patients with advanced cancer, particularly those with specific mutations.
Facilitates targeted therapy selection and improves treatment outcomes.
Clinical Best Practices
Incorporate liquid biopsy results into clinical decision-making. Use the assay in conjunction with other diagnostic tools for comprehensive care. Related Resources & Content
